BOSTON, Feb. 23, 2026 — Haemonetics Corporation announced that the U.S. Food and Drug Administration granted 510(k) clearance for its NexSys® PCS Plasma Collection System with Persona® PLUS technology, a next-generation platform designed to optimize plasma collection efficiency and donor personalization. The clearance was supported by data from a large prospective, randomized, multicenter trial involving more than 30,000 plasma donations, demonstrating the system’s safety, effectiveness, and improved plasma yield per donation.
Science Significance
The clearance marks a notable scientific advancement in plasma collection technology, particularly through the integration of personalized donation algorithms. Persona PLUS technology tailors plasma collection parameters to individual donor physiology, enabling optimized collection volumes while maintaining donor safety. Clinical evidence demonstrated a mid-single-digit percentage increase in plasma yield per donation, reflecting meaningful gains in biologic material recovery. Plasma serves as the foundational raw material for manufacturing plasma-derived medicinal products, including immunoglobulins, albumin, and clotting factors. Innovations that enhance plasma yield and donor experience directly strengthen the biologics supply chain and support expanding therapeutic demand.
Regulatory Significance
From a regulatory standpoint, the FDA’s 510(k) clearance confirms that the NexSys PCS system meets stringent U.S. safety and performance standards for medical devices. Approval was underpinned by robust clinical data generated through a prospective, randomized, controlled, multicenter pivotal trial, reinforcing device reliability and operational safety. Regulatory validation is particularly critical in plasma collection, where device performance affects donor well-being, biologic product integrity, and downstream manufacturing compliance. The system’s integrated design supporting traceability, quality monitoring, and operational standardization aligns with broader expectations around regulated blood and plasma collection infrastructure.
Business Significance
Advertisement
Commercially, the clearance strengthens Haemonetics’ leadership position in the global plasma collection market. The NexSys PCS platform is engineered to increase productivity, lower cost-per-liter, and enhance operational scalability for plasma centers facing rising global demand. By improving plasma yield and collection efficiency, Persona PLUS technology enables collection networks to expand supply without proportional increases in donor volume or infrastructure investment. This advancement supports cost optimization strategies while reinforcing Haemonetics’ competitive differentiation in integrated plasma collection solutions.
Patients’ Significance
For patients reliant on plasma-derived therapies, the technology carries profound clinical implications. Plasma-based biologics are essential for treating immune deficiencies, bleeding disorders, neurological conditions, and rare diseases. Supply shortages have historically constrained patient access worldwide. By enabling higher plasma collection yields and improved donor retention, the NexSys PCS system supports a more stable therapeutic supply chain. This translates into enhanced treatment continuity, reduced product shortages, and improved health outcomes for vulnerable patient populations dependent on life-sustaining biologics.
Policy Significance
The clearance also intersects with broader healthcare policy priorities focused on strengthening biologics manufacturing resilience. Governments and health systems are increasingly prioritizing plasma supply security, domestic fractionation capacity, and advanced collection infrastructure. Technologies that enhance collection efficiency align with public health objectives to ensure preparedness for chronic disease management and emergency therapeutic demand. Regulatory support for advanced collection systems reflects policy recognition of plasma as a strategic healthcare resource.
The FDA clearance of the NexSys PCS Plasma Collection System with Persona PLUS technology represents a significant convergence of device innovation, biologics supply optimization, and patient care advancement. By combining personalized donor analytics with scalable collection efficiency, Haemonetics is reinforcing the infrastructure that underpins plasma-derived therapeutics. As global demand for biologic medicines accelerates, next-generation plasma technologies will remain central to ensuring sustainable manufacturing pipelines and uninterrupted patient access to critical treatments.
Source: Haemonetics press release
